These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 26114738)

  • 41. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
    Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
    Saleem A; Waqar E; Shuja SH; Naeem U; Moeed A; Rais H; Ahmed J
    Transfus Clin Biol; 2023 Feb; 30(1):69-74. PubMed ID: 35878782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
    Takpradit C; Viprakasit V; Narkbunnam N; Vathana N; Phuakpet K; Pongtanakul B; Sanpakit K; Buaboonnam J
    Pediatr Int; 2021 Apr; 63(4):404-409. PubMed ID: 32856363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
    Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
    Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
    DivakarJose RR; Delhikumar CG; Ram Kumar G
    Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
    Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
    Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
    Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
    Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S; Hazirolan T; Eldem G; Gumruk F
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.
    Keshtkaran A; Javanbakht M; Salavati S; Mashayekhi A; Karimi M; Nuri B
    Transfusion; 2013 Aug; 53(8):1722-9. PubMed ID: 23241074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
    Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
    Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes.
    Yusuf S; Herdata HN; Edward ED; Khairunnisa K
    F1000Res; 2023; 12():154. PubMed ID: 39233713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox.
    Karimi M; Avazpour A; Haghpanah S; Toosi F; Badie A
    J Pediatr Hematol Oncol; 2017 Jan; 39(1):e11-e14. PubMed ID: 27548339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
    Shirley M; Plosker GL
    Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
    Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
    Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.